"Fondé en 1999 par les docteurs Pierre Lachance et René Therrien, le Centre de recherche Saint-Louis favorise l’épanouissement des sciences médicales à travers le monde"

During the past decade, Centre de Recherche Saint-Louis conducted 25 clinical trials. In the 10-year time frame, 25 clinical trials started and 16 clinical trials were completed, i.e. on average, 64% percent of trials that started reached the finish line to date. In the past 5 years, 12 clinical trials started and 13 clinical trials were completed. i.e. 108.3% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Centre de Recherche Saint-Louis" #1 sponsor was "Pfizer" with 20 trials, followed by "Hoffmann-La Roche" with 3 trials sponsored, "Medicago" with 2 trials sponsored, "Bayer" with 1 trials sponsored and "Concert Pharmaceuticals" with 1 trials sponsored. Other sponsors include -1 different institutions and companies that sponsored additional 9 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Centre de Recherche Saint-Louis" #1 collaborator was "Eli Lilly and Company" with 2 trials as a collaborator and "TIMI Study Group" with 1 trials as a collaborator. Other collaborators include -2 different institutions and companies that were collaborators in the rest 2 trials.

According to Clinical.Site data, the most researched conditions in "Centre de Recherche Saint-Louis" are "Rheumatoid Arthritis" (4 trials), "Alopecia Areata" (2 trials), "Atopic Dermatitis" (2 trials), "Nonalcoholic Fatty Liver Disease" (2 trials) and "Nonalcoholic Steatohepatitis" (2 trials). Many other conditions were trialed in "Centre de Recherche Saint-Louis" in a lesser frequency.

Most popular intervention types in "Centre de Recherche Saint-Louis" are "Drug" (22 trials), "Biological" (8 trials), "Device" (2 trials), "Other" (2 trials) and "Combination Product" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (14 trials), "Tocilizumab" (3 trials), "30 µg/strain of Quadrivalent VLP Vaccine" (2 trials), "Abrocitinib 200 mg" (2 trials) and "Methotrexate" (2 trials). Other intervention names were less common.

The vast majority of trials in "Centre de Recherche Saint-Louis" are 30 trials for "All" genders and 1 trials for "Female" genders.

Currently, there are NaN active trials in "Centre de Recherche Saint-Louis". undefined are not yet recruiting, 2 are recruiting, 4 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 24 completed trials in Centre de Recherche Saint-Louis, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in Centre de Recherche Saint-Louis, 0 "Phase 1" clinical trials were conducted, 14 "Phase 2" clinical trials and 13 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 1 trials, and there were also 2 trials that are defined as “Not Applicable".